 BEVERLY, Mass., July 02, 2021 GLOBE NEWSWIRE -- LexaGene Holdings, Inc., OTCQB: LXXGF; TSX-V: LXG the Company, a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today announced it continues to systematically advance the MiQLabTM System to meet the Food and Drug Administration FDA criteria for Emergency Use Authorization EUA. The MiQLab System is a first of its kind, point of care diagnostic testing technology. 